BACKGROUND/OBJECTIVES: Although adipokines and insulin resistance are known to be correlated with body fatness, it is unclear whether they are independently related to weight gain experience. We examined the associations of serum adipokines and marker of insulin resistance with past weight gain during adulthood by taking the degree of attained body mass index (BMI) level into consideration. SUBJECTS/METHODS: Subjects were 399 Japanese municipal employees, aged ⩾ 30 years, who participated in a health survey. Serum adipokines were measured using a Luminex suspension bead-based multiplexed array. Weight change during adulthood was calculated as the difference between measured current weight and recalled weight at the age of 20 years. Multiple regression was performed to calculate mean adipokine levels and homeostasis model assessment of insulin resistance (HOMA-IR) according to weight gain (o 5 kg, 5-9.9 kg, or ⩾ 10 kg) with adjustment for current BMI. RESULTS: Weight gain from the age of 20 years was significantly and positively associated with leptin levels even after adjustment for current BMI (P for trend o 0.001), whereas it was significantly and inversely associated with adiponectin levels in a BMI-adjusted model among subjects aged ⩾ 40 years (P for trend = 0.03). Weight gain was associated with HOMA-IR in a BMI-unadjusted model (P for trend o 0.001), but this association was largely attenuated after adjustment for BMI. Resistin, plasminogen activator inhibitor-1 and visfatin were not associated with past weight gain. CONCLUSIONS: Results suggest that a large weight gain during adulthood is associated with higher leptin and lower adiponectin levels independently of the degree of attained BMI level.
INTRODUCTION
Obesity is an important risk factor for diabetes mellitus, hypertension, cardiovascular disease and cancer, 1,2 and it is a major public health problem worldwide. 3, 4 A large weight gain commonly occurs during the period from late adolescence (18) (19) (20) years old) to middle age (30-55 years old). 5 Long-term weight gain during adulthood has been linked to an increased risk of mortality, 6, 7 cancer, 8, 9 coronary heart disease, 10 type 2 diabetes 11, 12 and metabolic syndrome. 13, 14 Given that these associations remained statistically significant even after adjustment for baseline body mass index (BMI), 6, 7, 10, 11, 13, 14 weight gain during adulthood may have a role in the etiology of these diseases, independently of attained BMI level. Biomarker study could contribute to the understanding of the mechanism underlying the association between weight gain and disease risk.
Adipose tissue is an endocrine organ, and it secretes various adipokines including adiponectin, leptin, resistin, plasminogen activator inhibitor-1 (PAI-1) and visfatin. 15, 16 Low adiponectin and high leptin, resistin, PAI-1 and visfatin levels may induce insulin resistance and associated metabolic complications, 17 and they have been linked to an increased risk of type 2 diabetes, 18 cardiovascular disease, 19 colorectal cancer 20 and nonalcoholic fatty liver disease. 21 Studies have shown that leptin, 22, 23 PAI-1, 24 visfatin 25 and resistin 26 increased with BMI, whereas adiponectin decreased with BMI; 27 however, epidemiological data on the association between these adipokines and weight gain during adulthood are scarce. In a Polish study, 28 women who experienced a large weight gain since the age of 20 years had lower adiponectin concentrations and higher homeostasis model assessment of insulin resistance (HOMA-IR) than those who did not. However, the observed association may be accounted for by current BMI rather than by weight gain per se. Here, we examined the associations of various adipokines and HOMA-IR with weight gain from the age of 20 years in a Japanese working population taking attained BMI level into consideration. We hypothesized that weight gain from adulthood is associated with lower levels of adiponectin and higher levels of leptin, resistin, PAI-1, visfatin and HOMA-IR independently of the degree of attained BMI level.
MATERIALS AND METHODS

Study procedure and subjects
We conducted a health survey in 2009 in two municipal offices in Kyushu, Japan, the details of which have been described elsewhere. 29 In brief, 567 employees who agreed to participate (response rate 94%) were asked to fill out survey questionnaires, donate blood sample and provide their health checkup data, including anthropometric measurements, biochemical data and information about medical history, smoking and alcohol consumption. For the present analysis, we excluded subjects with a history 1 of diabetes (n = 8), cancer (n = 13) and cardiovascular disease (n = 11), those under medication owing to chronic hepatitis (n = 3), pregnant women (n = 8), those who did not answer the question on weight at the age of 20 years (n = 65), those whose adipokine levels were not measured (n = 17) and those who received checkup in nonfasting condition (n = 21). In addition, we excluded subjects under the age of 30 years to examine the influence of long-term weight gain in adulthood (n = 28). Some of the excluded subjects had two or more criteria for exclusion. Finally, 399 subjects (238 men and 161 women, mean age: 45.6 ± 9.8) remained for analysis. The analysis of visfatin was carried out for 397 subjects after excluding those with visfatin levels exceeding detectable limits (n = 2). The study protocol was approved by the Ethics Committee of the National Center for Global Health and Medicine, Japan, and written informed consent was obtained from all participants.
Laboratory procedures
After an overnight fast, venous blood (7 ml) was drawn into a vacuum tube and centrifuged, and the separated serum samples were stored at -80°C. Adiponectin, leptin, resistin, PAI-1 and visfatin were measured by Bio-Plex 3D (Bio-Rad Laboratories, Hercules, CA, USA) using the Bio-Plex Pro Human Diabetes Assay kit (Bio-Rad Laboratories), a Luminex suspension beadbased multiplexed array. Luminex technology, which enables simultaneous assessment of multiple biomarkers, has been widely used. The system requires only a small amount of clinical samples, and good correlation with enzyme-linked immunosorbent assay and the usefulness for epidemiological studies have been well demonstrated. 30 The intra-assay coefficients of variation were 8% for resistin, 11% for leptin, 12% for adiponectin, 19% for visfatin and 21% for PAI-1. Serum insulin was determined with chemiluminescence immunoassay at an external laboratory (LSI Medience Corporation, Tokyo, Japan), with the intra-assay coefficients of variation being 2.5% at 43.1 pmol/l and 1.2% at 423 pmol/l. Plasma glucose was measured enzymatically using Glucose Cll-test Wako (Wako Pure Chemical Industries, Osaka, Japan) with OLYMPUS AU640 (Olympus Corp., Tokyo, Japan). We computed the HOMA-IR using the following formula: [fasting insulin (μU/ml) × fasting glucose (mmol/l)]/22.5. 31 
BMI and weight gain
Body height was measured at the health checkup to the nearest 0.1 cm, with subjects standing without shoes. Body weight in light clothes was measured to the nearest 0.1 kg. BMI was calculated by dividing weight by squared height (kg/m 2 ). Body weight at the age of 20 years was obtained via questionnaire. Weight change during adulthood was calculated as the difference between measured current weight and recalled weight at the age of 20 years, and divided into three categories (o5, 5-9.9 or ⩾ 10 kg). Subjects who lost weight were included in the category of o5 kg.
Lifestyle assessment
We classified occupational physical activity as either sedentary or active on the basis of the job title. As regards nonoccupational physical activity, we asked participants about walking or cycling for commute to or from work and recreational activities (walking, low-, moderate-and high-intensity activities, and gardening) and estimated the total level of these activities in metabolic equivalent-hours (MET-hr) with reference to relevant data. 32 
Statistical analyses
The characteristics of study subjects were expressed as mean (standard deviation) and percentages according to weight gain; trend associations were evaluated using linear regression analysis for continuous variables, with 0-2 assigned to weight gain categories and Mantel-Haenszel chi-square test for categorical variables. Analysis of covariance was performed to estimate geometric means and 95% confidence intervals of adipokine concentrations and HOMA-IR after log transformation. Multiple linear regression was used to test the trend association between weight gain and outcome variables by assigning 0-2 to the weight gain categories. Confounding variables considered were age (years, continuous), sex and workplace (model 1). In model 2, further adjustment was made for occupational physical activity (sedentary or active work), nonoccupational physical activity (0, 0o to o 5, or ⩾ 5 METs-hr/week), smoking status (nonsmoker, quitter, current smoker consuming 1 ⩽ to o20 cigarettes/day or current smoker consuming ⩾ 20 cigarettes/day), alcohol use (0, 0o to o20, or ⩾ 20 g ethanol/day) and parental history of diabetes (yes or no). In model 3, current BMI (kg/m 2 , continuous) was additionally adjusted for. To examine the association of long-term weight change (⩾20 years from the age of 20 years), we repeated the model 3 analysis in subjects aged ⩾ 40 years (n = 249, model 4). As a sensitivity analysis, we repeated the above analyses after excluding subjects who showed a large weight loss (more than 5 kg) and adjusted for waist circumference instead of BMI. In addition, we examined the association between weight gain from the age of 20 years and HOMA-IR (n = 399) while additionally adjusting for adiponectin and leptin (model 5) and current BMI (model 6). We also performed analysis by sex and adjusted for menopausal status in women. To examine effect modification by sex, we added an interaction term of sex and weight gain to models. Two-sided P values o0.05 were regarded as statistically significant. All analyses were performed by using SAS statistical software version 9.3 (SAS Institute, Cary, NC, USA).
RESULTS
The characteristics of study participants according to weight gain are shown in Table 1 29.2 kg and 22.5 ± 3.2 kg/m 2 , respectively. Participants who experienced a greater weight gain, compared with those with less weight gain, were older and more likely to be male and current smokers and had a higher BMI at the time of the survey and lower BMI at the age of 20 years. There was no significant difference across the weight gain category for sedentary work, physical activity, alcohol use and parental history of diabetes. Leptin and adiponectin were associated with current BMI; the Spearman's correlation coefficients were 0.43 and -0.43, respectively. Other adipokines were not associated with current BMI; the Spearman's correlation coefficients for resistin, PAI-1 and visfastin were − 0.01, 0.15 and 0.07, respectively. The relationship between weight gain and adipokines is shown in Table 2 . A positive association was observed for weight gain and leptin in the BMIunadjusted model (model 2; P for trend o0.001), and this association remained statistically significant after further adjustment for BMI (model 3; P for trend o0.001). Similar results were obtained when analyses were repeated among participants aged ⩾ 40 years. Adiponectin showed a statistically significant inverse relationship with weight gain in BMI-unadjusted model (model 2; P for trend o0.001). In model 3, where BMI was further adjusted for, the association was attenuated (P for trend = 0.11), but it was statistically significant among participants aged ⩾ 40 years (P for trend = 0.03). These associations materially unchanged in a model that adjusted for waist circumference instead of BMI (data not shown in table). Resistin, PAI-1 and visfatin were not associated with weight gain in any model. When the above analyses were repeated after excluding subjects who showed a large weight loss (more than 5 kg) from the age of 20 years, results were not substantially changed (data not shown in table). Higher weight gain was significantly associated with higher values of HOMA-IR (model 2; P for trend o0.001). This association was materially A or B ). e Additionally adjusted for occupational physical activity (sedentary or active work), nonoccupational physical activity (0, 0 o to o5, or ⩾ 5 METs-hr/week), smoking status (nonsmoker, quitter, current smoker consuming 1 ⩽ to o20 cigarettes/day or current smoker consuming ⩾ 20 cigarettes/day), alcohol use (0, 0 o to o20, or ⩾ 20 g ethanol/day) and parental history of diabetes (yes or no). f Additionally adjusted for current BMI (kg/m 2 , continuous). g Adjusted for the variables of model 3 on subjects aged 40 years or over (n = 249, weight gain categories o5 kg; n = 130, 5-9.9 kg; n = 61, ⩾ 10 kg; n = 58). h n = 397 (weight gain categories o5 kg; n = 226, 5-9.9 kg; n = 91, ⩾ 10 kg; n = 80). i Additionally adjusted for adiponectin, and leptin in model 2.
j Additionally adjusted for current BMI (kg/m 2 , continuous) in model 5.
Adulthood weight gain and adipokine levels Y Kimura et al unchanged after further adjustment for adiponectin and leptin (model 5; P for trend o0.001), but it was largely attenuated after adjustment for current BMI (model 6; P for trend = 0.46). The interaction by weight gain and sex did not attain statistical significance for any adipokine (P for interaction = 0.39, 0.08, 0.21, 0.94, 0.16 and 0.16 for adiponectin, leptin, resistin, PAI-1, visfatin and HOMA-IR, respectively). In analysis stratified by sex (model 3, where menopausal status was additionally adjusted for women); however, the leptin-weight gain association was statistically significant in men (P for trend o0.001) but not in women (P for trend = 0.41), whereas the HOMA-IR-weight gain association was statistically significant in women (P for trend = 0.04) but not in men (P for trend = 0.46).
DISCUSSION
In a cross-sectional study among Japanese workers, we found a positive association between leptin concentrations and weight gain from the age of 20 years even after adjustment for current BMI. In addition, an inverse association was observed between adiponectin concentrations and past weight gain among subjects aged 40 years or more independently of current BMI. To our knowledge, this is the first study to examine adipokine concentrations in relation to long-term weight gain during adulthood with consideration of attained BMI level, which is critical to assess whether weight gain experience per se is associated with current adipokine levels.
In the present study, the association between leptin and weight gain was the strongest among the examined adipokines. This result is compatible with epidemiological data showing a strong and consistent association between leptin and body fat; [33] [34] [35] the Pearson correlation coefficients of leptin, adiponectin, resistin and visfatin with fat mass measured using dual-energy X-ray absorptiometry were 0.58, − 0.22, 0.06 and 0.03, respectively, 33 and fat mass measured with bioelectric impedance analysis was strongly positively correlated with leptin (r = 0.85) 34 and was inversely correlated with adiponectin (r = − 0.27). 35 Furthermore, the positive association between leptin and weight gain persisted even after adjustment for current BMI, suggesting a significant role of weight gain independent of attained weight. Given that weight gain in adulthood is largely explained by the increase of body fat, 36 a person who experienced a large weight gain during adulthood might have a greater proportion of body fat and thus higher leptin levels than those who have a similar weight but experienced little weight change.
A Polish cross-sectional study showed that women with a large weight gain during adulthood (⩾10 kg) had much lower adiponectin levels than those with less weight gain (o 10 kg). 28 However, that study did not adjust for BMI, and it is thus unclear whether the association with weight gain is independent of attained BMI. In the present study, an inverse association between adiponectin and weight gain in the BMI-adjusted model was not evident among overall subjects, but it became statistically significant among those aged ⩾ 40 years. This finding suggests that weight gain during adulthood encompassing middle age independently predicts circulating adiponectin levels. This result is compatible with data showing that adiponectin levels are inversely correlated with the accumulation of visceral adipose tissue, 37 which increases mainly during middle age. 38 Weight gain during the period of middle age but not during young adulthood may have a significant impact on adiponectin levels.
In the present study, neither weight gain from the age of 20 years nor current BMI was associated with resistin, PAI-I and visfatin. Several, [24] [25] [26] 39, 40 but not all, 33, 41 studies reported a positive association between obesity and these adipokines. Although we have no plausible explanation for such discrepant findings among studies, this may be ascribed to the difference in the level of BMI. Subjects in the present study were on average much leaner (mean BMI 22.5 kg/m 2 ) than those in studies with a positive association (29.5 kg/m 2 (ref. 24), 26.7 kg/m 2 (ref. 39) ]. The association of resistin, PAI-I and visfatin with fatness may be detected only at high levels of body fatness. Alternatively, relatively greater variation of measurement for PAI-1 (21%) and visfatin (19%) might have diluted the association.
An apparent association between weight gain and insulin resistance of the present study is in agreement with a Polish study reporting a higher mean of HOMA-IR among those who experienced a large weight gain from the age of 20 years (above 30 kg). 28 In our study, however, this association was attenuated and it was no longer statistically significant after adjustment for current BMI, suggesting that the weight gain-insulin resistance association could be largely explained by the degree of attained BMI level. Nevertheless, given a close correlation between past weight gain and current weight in our data (r = 0.59), the suppression of weight gain throughout adulthood is a practical strategy to maintain insulin sensitivity.
In the present study, weight gain was associated with leptin in men only, whereas it was associated with HOMA-IR in women only, suggesting a gender difference of the effect of weight gain on adipokine and insulin resistance. This result, however, should be interpreted with caution because the sample size was not sufficiently large for stratified analysis, and P for interactions did not reach statistical significance. Larger-scale studies are needed to elucidate gender difference of these associations.
Strengths of this study include its high participation rate (94%) and adjustment for potential confounders. This study also has several limitations. First, the use of self-reported data on weight at the age of 20 years may not be precise. In a validation study that asked participants, aged 34-61 years, to recall their weight at the age of 25, 42 recalled weight was strongly correlated with recorded weight (r = 0.85); however, men who lost weight since the age of 25 years tended to underestimate weight at the age of 25 years, whereas men who gained weight tended to overestimate their past weight, and the degree of underestimation and overestimation increased as the degree of weight loss and gain increased, respectively. Therefore, those who experienced a greater weight gain in the present study might have overestimated their weight at the age of 20 years, leading to an underestimation of weight gain, which was calculated as the difference between recalled weight at the age of 20 years and current weight. The resulting misclassification would underestimate the association of weight gain with adipokine and insulin resistance. Second, we measured biomarker levels at only a single time point. A previous study showed, however, that adipokine levels in a single blood sample were highly correlated with the mean of those in the samples obtained in the three remaining seasons (r = 0.84 for leptin and r = 0.89 for adiponectin). 43 Third, detailed information on history of weight gain was not obtained, and it is thus unclear whether weight gain in different periods of lifetime has a differential impact on these adipokines. Fourth, we cannot exclude a possibility of bias due to unmeasured confounders and residual confounding. For instance, we did not assess the influence of weight cycling, which has been suggested to have a role in the pathogenesis of coronary heart disease 44 and cancer 45 and thus may partly explain the association between weight gain and adipokines. Finally, our study was conducted among municipal office workers in Japan. Caution is required in generalizing the present findings.
In conclusion, weight gain during adulthood was associated with serum levels of leptin and adiponectin independently of current BMI. Given the numerous physiological and pathological roles of leptin and adiponectin, weight gain may increase the risk of diseases, at least in part, through changes in these adipokines. Studies with longitudinal measurements of adipokine levels, as well as weight, are required to confirm the present cross-sectional associations.
